Atlas Trials

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

Clinical trial NCT03855917 · RECRUITING

Trial details

NCT number
NCT03855917
Sponsor
Kirby Institute
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Hepatitis C
Start date
2020-02-11
Primary completion
2029-07-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.